Drug
EE20/DRSP (YAZ, BAY86-5300)
EE20/DRSP (YAZ, BAY86-5300) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_3
2
50%
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 32 (66.7%)
Phase 41 (33.3%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_4
YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China
NCT02710708
completed
Regulatory Post Marketing Surveillance Study on YAZ
NCT00998257
completedphase_3
Comparative Trial in Hormone Withdrawal Associated Symptoms
NCT01076582
completedphase_3
Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ
NCT00567164
Clinical Trials (4)
Showing 4 of 4 trials
NCT02710708Phase 4
YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China
NCT00998257
Regulatory Post Marketing Surveillance Study on YAZ
NCT01076582Phase 3
Comparative Trial in Hormone Withdrawal Associated Symptoms
NCT00567164Phase 3
Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4